1,3-Disubstituted cyclopentane derivatives

1. Compounds of the formula I

in which

R denotes Ar or Het,

Y denotes —CO—W or —N(R 4 )CO—W 1 ,

W denotes NR 2 R 2′ , CH 2 Het 1 , A, Cyc, Ar, CH 2 Ar, —CONR 2 R 2′ or Het 1 ,

W 1 denotes NR 2 R 2′ , Het 1 , CH 2 Het 1 , A, Cyc, Ar, CH 2 Ar, CH 2 Cyc or CH(OH)CH 2 OH,

R 1 denotes H, F, Cl, Br, OH, CN, NO 2 , A′, OA′, SA′, SO 2 Me, COA′, CONH 2 , CONHA′ or CONA′ 2 ,

R 2 and R 2′ each, independently of one another, denote H, A or [C(R 3 ) 2 ] n Cyc,

X 1 , X 2 and X 3 each, independently of one another, denote CR 8 or N,

X 4 denotes CR 8 or N,

X 5 denotes CR 8 or N,

R 4 denotes H or A′,

A denotes unbranched or branched alkyl with 1-10 C-atoms, wherein two adjacent carbon atoms may form a double bond and/or one or two non-adjacent CH- and/or CH 2 -groups may be replaced by N-, O- and/or S-atoms and wherein 1-7 H-atoms may be replaced by R 5 ,

Cyc denotes cycloalkyl with 3-7 C-atoms, which is unsubstituted or monosubstituted by OH, Hal or A,

A′ denotes unbranched or branched alkyl with 1-6 C-atoms, wherein 1-5 H-atoms may be replaced by F,

R 5 denotes F, Cl or OH,

Ar denotes phenyl, which is unsubstituted or mono-, di-, tri-, tetra- or pentasubstituted by Hal, A, O[C(R 3 ) 2 ] n Het 1 , Ar 1 , [C(R 3 ) 2 ] p OR 3 , [C(R 3 ) 2 ] p N(R 3 ) 2 , NO 2 , CN, [C(R 3 ) 2 ] p COOR 3 , CON(R 3 ) 2 , Het 1 , OCH 2 Cyc, N(R 3 ) 2 COA, NR 3 SO 2 A, [C(R 3 ) 2 ] p SO 2 N(R 3 ) 2 , S(O) n A, O[C(R 3 ) 2 ] m N(R 3 ) 2 , NHCOOA, NHCON(R 3 ) 2 and/or COA,

Ar 1 denotes phenyl or naphthyl, which is unsubstituted or mono-, di-, tri-, tetra- or pentasubstituted by Hal, A, [C(R 3 ) 2 ] p OR 3 , [C(R 3 ) 2 ] p N(R 3 ) 2 , NO 2 , CN, [C(R 3 ) 2 ] p COOR 3 , [C(R 3 ) 2 ] p N(R 3 ) 2 , N(R 3 ) 2 COA, NR 3 SO 2 A, [C(R 3 ) 2 ] p SO 2 N(R 3 ) 2 , S(O) n A, O[C(R 3 ) 2 ] m N(R 3 ) 2 , NHCOOA, NHCON(R 3 ) 2 and/or COA,

R 3 denotes H or unbranched or branched alkyl with 1-6 C-atoms,

R 8 denotes H or A′,

Het denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which is unsubstituted or mono-, di-, tri-, tetra- or pentasubstituted by Hal, A, [C(R 3 ) 2 ] n OA′, [C(R 3 ) 2 ] n N(R 3 ) 2 , SR 3 , NO 2 , CN, COOR 3 , CON(R 3 ) 2 , COHet 1 , NR 3 COA, NR 3 SO 2 A, SO 2 N(R 3 ) 2 , S(O) n A,

O[C(R 3 ) 2 ] m N(R 3 ) 2 , NHCOOA, NHCON(R 3 ) 2 , CHO, COA, ═S, ═NH, ═NA and/or ═O (carbonyl oxygen),

Het 1 denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which is unsubstituted or mono-, di-, tri-, tetra- or pentasubstituted by Hal, A, [C(R 3 ) 2 ] n OR 3 , [C(R 3 ) 2 ] n N(R 3 ) 2 , SR 3 , NO 2 , CN, COOR 3 , CON(R 3 ) 2 , NR 3 COA, NR 3 SO 2 A, SO 2 N(R 3 ) 2 , S(O) n A,

O[C(R 3 ) 2 ] m N(R 3 ) 2 , NHCOOA, NHCON(R 3 ) 2 , CHO, COA, ═S, ═NH, ═NA and/or ═O (carbonyl oxygen),

Hal denotes F, Cl, Br or I,

m denotes 1, 2 or 3,

n denotes 0, 1 or 2,

p denotes 0, 1, 2, 3 or 4,

q denotes 0, 1, 2 or 3,

and pharmaceutically acceptable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

2. Compounds according to claim 1 in which

R 4 denotes H, and pharmaceutically acceptable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

3. Compounds according to claim 1 , in which

A denotes unbranched or branched alkyl with 1-6 C-atoms, and pharmaceutically acceptable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

4. Compounds according to claim 1 , in which

Ar denotes phenyl, which is unsubstituted or mono-, di- or trisubstituted by Hal, A, Het 1 , [C(R 3 ) 2 ] p OR 3 , [C(R 3 ) 2 ] p COOR 3 , OCH 2 Cyc, CON(R 3 ) 2 and/or CN,

and pharmaceutically acceptable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

5. Compounds according to claim 1 , in which

Het denotes a mono- or bicyclic aromatic heterocycle having 1 to 4 N, O and/or S atoms, which is unsubstituted or mono- or disubstituted by Hal, A and/or ═O,

and pharmaceutically acceptable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

6. Compounds according to claim 1 , in which

Het denotes furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridyl, pyrimidinyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, pyridazinyl, pyrazinyl, benzoxazolyl, benzothiazolyl, benzimidazolyl, benzotriazolyl, indolyl, benzo-1,3-dioxolyl, benzodioxanyl, benzothiadiazolyl, indazolyl, benzofuranyl, quinolyl, isoquinolyl, pyrrolo[2,3-b]pyridyl, oxazolo[5,4-b]pyridyl, imidazo[1,2-a]pyrimidinyl, 2,3-dihydro-indolyl, 2,3-dihydro-benzimidazolyl, imidazo[1,2-a]pyridyl, pyrrolo[3,2-b]pyridyl or oxazolo[5,4-c]pyridyl, each of which is unsubstituted or mono- or disubstituted by Hal, A and/or ═O,

and pharmaceutically acceptable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

7. Compounds according to claim 1 , in which

Het 1 denotes furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridyl, pyrimidinyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, pyridazinyl, pyrazinyl, tetrahydrofuranyl, [1,3]dioxolanyl, pyrrolidinyl, piperidinyl or morpholinyl, each of which is unsubstituted or mono- or disubstituted by Hal, A and/or ═O,

and pharmaceutically acceptable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

8. Compounds according to claim 1 , in which

R denotes Ar or Het,

Y denotes —CO—W or —N(R 4 )CO—W 1 ,

W denotes NR 2 R 2′ ,

W 1 denotes A, Cyc, Het 1 , CH 2 Cyc or CH(OH)CH 2 OH,

R 1 denotes H or F,

R 2 and R 2′ each, independently of one another, denote H, A or [C(R 3 ) 2 ] n Cyc,

X 1 , X 2 , X 3 each, independently of one another, denote CR 8 or N,

X 4 denotes CR 8 or N,

X 5 denotes CR 8 or N,

R 4 denotes H,

A denotes unbranched or branched alkyl with 1-6 C-atoms,

Cyc denotes cycloalkyl with 3-7 C-atoms, which is unsubstituted or monosubstituted by A,

A′ denotes unbranched or branched alkyl with 1-6 C-atoms,

Ar denotes phenyl, which is unsubstituted or mono-, di- or trisubstituted by Hal, A, Het 1 , [C(R 3 ) 2 ] p OR 3 , [C(R 3 ) 2 ] p COOR 3 , OCH 2 Cyc, CON(R 3 ) 2 and/or CN,

R 3 denotes H or unbranched or branched alkyl with 1-6 C-atoms,

R 8 denotes H or A′,

Het denotes a mono- or bicyclic aromatic heterocycle having 1 to 4 N, O and/or S atoms, which is unsubstituted or mono- or disubstituted by Hal, A and/or ═O,

Het 1 denotes furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridyl, pyrimidinyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, pyridazinyl, pyrazinyl, tetrahydrofuranyl, [1,3]dioxolanyl, pyrrolidinyl, piperidinyl or morpholinyl, each of which is unsubstituted or mono- or disubstituted by Hal, A and/or ═O,

Hal denotes F, Cl, Br or I,

n denotes 0, 1 or 2,

p denotes 0, 1, 2, 3 or 4,

q denotes 1,

and pharmaceutically acceptable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

9. Compounds according to claim 1 , selected from the group consisting of

No.

Name

“A1”

4-(1,3-benzoxazol-2-yl)-N-[(1R,3S)-3-

(ethylcarbamoyl)cyclopentyl]-N-methyl-benzamide,

“A2”

(1S,3R)-3-(5-biphenyl-4-yl-imidazol-1-yl)-

cyclopentanecarboxylic acid ethylamide,

“A3”

(1S,3R)-3-[5-(4′-Chloro-biphenyl-4-yl)-imidazol-1-yl]-

cyclopentanecarboxylic acid ethylamide,

“A4”

(1S,3R)-3-[5-(4-benzoxazol-2-yl-phenyl)-imidazol-1-yl]-

cyclopentanecarboxylic acid (1-methyl-cyclopropyl)-amide,

“A5”

(1S,3R)-3-{5-[4-(1H-pyrrolo[2,3-b]pyridin-5-yl)-phenyl]-

imidazol-1-yl}-cyclopentanecarboxylic acid (1-methyl-

cyclopropyl)-amide,

“A6”

(1S,3R)-3-[5-(4-benzothiazol-6-yl-phenyl)-imidazol-1-yl]-

cyclopentanecarboxylic acid (1-methyl-cyclopropyl)-amide

amide,

“A7”

(1S,3R)-3-{5-[4-(1H-indol-6-yl)-phenyl]-imidazol-1-yl}-

cyclopentanecarboxylic acid (1-methyl-cyclopropyl)-amide,

“A8”

(1S,3R)-3-{5-[4-(5-fluoro-1H-indol-2-yl)-phenyl]-imidazol-1-

yl}-cyclopentanecarboxylic acid (1-methyl-cyclopropyl)-amide,

“A9”

(1S,3R)-3-{5-[4-(1H-benzotriazol-5-yl)-phenyl]-imidazol-1-yl}-

cyclopentanecarboxylic acid (1-methyl-cyclopropyl)-amide,

“A10”

(1S,3R)-3-{5-[4-(1H-indol-5-yl)-phenyl]-imidazol-1-yl}-

cyclopentanecarboxylic acid (1-methyl-cyclopropyl)-amide,

“A11”

(1S,3R)-3-{5-[4-(1H-indazol-4-yl)-phenyl]-imidazol-1-yl}-

cyclopentanecarboxylic acid (1-methyl-cyclopropyl)-amide,

“A12”

(1S,3R)-3-[5-(4′-cyano-biphenyl-4-yl)-imidazol-1-yl]-

cyclopentanecarboxylic acid (1-methyl-cyclopropyl)-amide,

“A13”

(1S,3R)-3-[5-(4-benzoxazol-2-yl-phenyl)-[1,2,3]triazol-1-yl]-

cyclopentanecarboxylic acid ethylamide,

“A14”

(1S,3R)-3-[5-(4′-chloro-biphenyl-4-yl)-[1,2,3]triazol-1-yl]-

cyclopentanecarboxylic acid ethylamide,

“A15”

(1S,3R)-3-[5-(4′-cyano-biphenyl-4-yl)-[1,2,3]triazol-1-yl]-

cyclopentanecarboxylic acid ethylamide,

“A16”

(1S,3R)-3-{5-[4-(1H-indol-6-yl)-phenyl]-[1,2,3]triazol-1-yl}-

cyclopentanecarboxylic acid ethylamide,

“A17”

(1S,3R)-3-[5-(4-benzoxazol-2-yl-phenyl)-[1,2,3]triazol-1-yl]-

cyclopentanecarboxylic acid (1-methyl-cyclopropyl)-amide,

“A18”

(1S,3R)-3-[5-(4-benzoxazol-2-yl-phenyl)-[1,2,3]triazol-1-yl]-

cyclopentanecarboxylic acid propylamide,

“A19”

N-{(1S,3R)-3-[5-(4-benzoxazol-2-yl-phenyl)-imidazol-1-yl]-

cyclopentyl}-propionamide,

“A20”

N-{(1S,3R)-3-[5-(4-benzothiazol-2-yl-phenyl)-imidazol-1-yl]-

cyclopentyl}-propionamide,

“A21”

N-{(1S,3R)-3-[5-(4′-chloro-biphenyl-4-yl)-imidazol-1-yl]-

cyclopentyl}-propionamide,

“A22”

N-((1S,3R)-3-{5-[4-(1H-indazol-4-yl)-phenyl]-imidazol-1-yl}-

cyclopentyl)-propionamide,

“A23”

N-{(1S,3R)-3-[5-(4-benzoxazol-2-yl-phenyl)-[1,2,3]triazol-

1-yl]-cyclopentyl}-propionamide,

“A24”

N-{(1S,3R)-3-[5-(4-benzoxazol-2-yl-phenyl)-[1,2,3]triazol-

1-yl]-cyclopentyl}-acetamide,

“A25”

N-{(1S,3R)-3-[5-(4′-chloro-biphenyl-4-yl)-[1,2,3]triazol-1-yl]-

cyclopentyl}-propionamide,

“A26”

N-((1S,3R)-3-{5-[4-(1H-indazol-4-yl)-phenyl]-[1,2,3]triazol-

1-yl}-cyclopentyl)-propionamide,

“A27”

N-((1S,3R)-3-{5-[4-(1H-indol-5-yl)-phenyl]-[1,2,3]triazol-

1-yl}-cyclopentyl)-propionamide,

“A28”

N-{(1S,3R)-3-[5-(4-benzothiazol-2-yl-phenyl)-[1,2,3]triazol-

1-yl]-cyclopentyl}-propionamide,

“A29”

(1S,3R)-3-[3-(4-benzoxazol-2-yl-phenyl)-[1,2,4]triazol-4-yl]-

cyclopentanecarboxylic acid ethylamide,

“A30”

(1S,3R)-3-{3-[4-(1H-indol-6-yl)-phenyl]-[1,2,4]triazol-4-yl}-

cyclopentanecarboxylic acid ethylamide,

“A31”

(1S,3R)-3-[3-(4′-chloro-biphenyl-4-yl)-[1,2,4]triazol-4-yl]-

cyclopentanecarboxylic acid ethylamide,

“A32”

(1S,3R)-3-[3-(4′-cyano-biphenyl-4-yl)-[1,2,4]triazol-4-yl]-

cyclopentanecarboxylic acid ethylamide,

“A33”

(1S,3R)-3-[3-(4-benzothiazol-2-yl-phenyl)-[1,2,4]triazol-4-yl]-

cyclopentanecarboxylic acid ethylamide,

“A34”

(1S,3R)-3-[3-(4-benzothiazol-6-yl-phenyl)-[1,2,4]triazol-4-

yl]-cyclopentanecarboxylic acid (1-methyl-cyclopropyl)-amide,

“A35”

(1S,3R)-3-{3-[4-(1H-indazol-4-yl)-phenyl]-[1,2,4]triazol-

4-yl}-cyclopentanecarboxylic acid ethylamide,

“A36”

(1S,3R)-3-[3-(4-benzoxazol-2-yl-phenyl)-5-methyl-

[1,2,4]triazol-4-yl]-cyclopentanecarboxylic acid ethylamide,

“A37”

N-{(1S,3R)-3-[3-(4-benzoxazol-2-yl-phenyl)-[1,2,4]triazol-

4-yl]-cyclopentyl}-propionamide,

“A38”

N-{(1S,3R)-3-[3-(4-benzothiazol-2-yl-phenyl)-[1,2,4]triazol-4-

yl]-cyclopentyl}-propionamide,

“A39”

N-{(1S,3R)-3-[3-(4′-chloro-biphenyl-4-yl)-[1,2,4]triazol-4-yl]-

cyclopentyl}-propionamide,

“A40”

N-{(1S,3R)-3-[3-(4′-cyano-biphenyl-4-yl)-[1,2,4]triazol-4-yl]-

cyclopentyl}-propionamide,

“A41”

N-{(1S,3R)-3-[3-(4-benzoxazol-2-yl-phenyl)-5-ethyl-

[1,2,4]triazol-4-yl]-cyclopentyl}-propionamide,

“A42”

N-((1S,3R)-3-{3-[4-(1H-indazol-4-yl)-phenyl]-[1,2,4]triazol-4-

yl}-cyclopentyl)-propionamide,

“A43”

N-{(1S,3R)-3-[3-(4-benzothiazol-6-yl-phenyl)-[1,2,4]triazol-4-

yl]-cyclopentyl}-propionamide,

“A44”

N-((1S,3R)-3-{3-[4-(1H-indol-6-yl)-phenyl]-[1,2,4]triazol-4-yl}-

cyclopentyl)-propionamide,

“A45”

(1S,3R)-3-[5-(4-benzoxazol-2-yl-phenyl)-pyrazol-1-yl]-

cyclopentanecarboxylic acid ethylamide,

“A46”

N-{(1S,3R)-3-[5-(4-benzothiazol-2-yl-phenyl)-pyrazol-1-yl]-

cyclopentyl}-propionamide,

“A47”

(1S,3R)-3-{5-[4-(1H-Indazol-4-yl)-phenyl]-pyrazol-1-yl}-

cyclopentanecarboxylic acid ethylamide,

“A48”

(1S,3R)-3-[5-(4-benzothiazol-6-yl-phenyl)-pyrazol-1-yl]-

cyclopentanecarboxylic acid ethylamide,

“A49”

(1S,3R)-3-{5-[4-(1H-indol-6-yl)-phenyl]-pyrazol-1-yl}-

cyclopentanecarboxylic acid ethylamide,

“A50”

(1S,3R)-3-[5-(4′-chloro-biphenyl-4-yl)-pyrazol-1-yl]-

cyclopentanecarboxylic acid ethylamide,

“A51”

(1S,3R)-3-[5-(4′-cyano-biphenyl-4-yl)-pyrazol-1-yl]-

cyclopentanecarboxylic acid ethylamide,

“A52”

(1S,3R)-3-[5-(4-benzoxazol-2-yl-phenyl)-pyrazol-1-yl]-

cyclopentanecarboxylic acid ethylamide,

“A53”

N-{(1S,3R)-3-[5-(4-benzothiazol-2-yl-phenyl)-pyrazol-1-yl]-

cyclopentyl}-propionamide,

“A54”

N-{(1S,3R)-3-[5-(4′-cyano-biphenyl-4-yl)-pyrazol-1-yl]-

cyclopentyl}-propionamide,

“A55”

(N-{(1S,3R)-3-[5-(4′-chloro-biphenyl-4-yl)-pyrazol-1-yl]-

cyclopentyl}-propionamide,

“A56”

N-((1S,3R)-3-{5-[4-(1H-indazol-4-yl)-phenyl]-pyrazol-1-yl}-

cyclopentyl)-propionamide,

“A57”

N-((1S,3R)-3-{5-[4-(1H-indol-6-yl)-phenyl]-pyrazol-1-yl}-

cyclopentyl)-propionamide,

“A58”

N-{(1S,3R)-3-[5-(4′-Cyano-biphenyl-4-yl)-[1,2,3]triazol-1-yl]-

cyclopentyl}-propionamide,

“A59”

N-((1S,3R)-3-{5-[4-(1H-Indol-6-yl)-phenyl]-[1,2,3]triazol-

1-yl}-cyclopentyl)-propionamide,

“A60”

N-{(1S,3R)-3-[5-(4-Benzothiazol-6-yl-phenyl)-[1,2,3]triazol-1-

yl]-cyclopentyl}-propionamide,

“A61”

N-((1S,3R)-3-{5-[4-(1-Methyl-1H-indazol-5-yl)-phenyl]-

[1,2,3]triazol-1-yl}-cyclopentyl)-propionamide,

“A62”

N-{(1S,3R)-3-[5-(4′-Cyano-2′-fluoro-biphenyl-4-yl)-

[1,2,3]triazol-1-yl]-cyclopentyl}-propionamide,

“A63”

N-((1S,3R)-3-{5-[4-(1-Methyl-1H-indazol-6-yl)-phenyl]-

[1,2,3]triazol-1-yl}-cyclopentyl)-propionamide,

“A64”

N-((1S,3R)-3-{5-[4′-(1-Methyl-1H-pyrazol-4-yl)-biphenyl-

4-yl]-[1,2,3]triazol-1-yl}-cyclopentyl)-propionamide,

“A65”

(1S,3R)-3-[3-(4-Benzothiazol-6-yl-phenyl)-[1,2,4]triazol-

4-yl]-cyclopentanecarboxylic acid ethylamide,

“A66”

Cyclopropanecarboxylic acid {(1S,3R)-3-[5-(4-benzooxazol-2-

yl-phenyl)-[1,2,3]triazol-1-yl]-cyclopentyl}-amide,

“A67”

N-{(1S,3R)-3-[5-(4-Benzoxazol-2-yl-phenyl)-[1,2,3]triazol-

1-yl]-cyclopentyl}-2-cyclopentyl-acetamide,

“A68”

(R)-Tetrahydro-furan-2-carboxylic acid {(1S,3R)-3-[5-(4-

benzooxazol-2-yl-phenyl)-[1,2,3]triazol-1-yl]-cyclopentyl}-

amide,

“A69”

(S)-Tetrahydro-furan-2-carboxylic acid {(1S,3R)-3-[5-(4-

benzooxazol-2-yl-phenyl)-[1,2,3]triazol-1-yl]-cyclopentyl}-

amide,

“A70”

N-{(1S,3R)-3-[5-(4-Quinolin-3-yl-phenyl)-[1,2,3]triazol-1-yl]-

cyclopentyl}-propionamide,

“A71”

N-((1S,3R)-3-{5-[4-(1-Methyl-1H-indol-5-yl)-phenyl]-

[1,2,3]triazol-1-yl}-cyclopentyl)-propionamide,

“A72”

N-((1S,3R)-3-{5-[4-(1H-Indazol-6-yl)-phenyl]-[1,2,3]triazol-1-

yl}-cyclopentyl)-propionamide,

“A73”

N-((1S,3R)-3-{5-[4-(1H-Benzimidazol-5-yl)-phenyl]-

[1,2,3]triazol-1-yl}-cyclopentyl)-propionamide,

“A74”

N-((1S,3R)-3-{5-[4-(1H-Indazol-5-yl)-phenyl]-[1,2,3]triazol-1-

yl}-cyclopentyl)-propionamide,

“A75”

N-{(1S,3R)-3-[5-(4′-Chloro-3′-fluoro-biphenyl-4-yl)-

[1,2,3]triazol-1-yl]-cyclopentyl}-propionamide,

“A76”

N-{(1S,3R)-3-[5-(4′-Pyrazol-1-yl-biphenyl-4-yl)-[1,2,3]triazol-

1-yl]-cyclopentyl}-propionamide,

“A77”

N-((1S,3R)-3-{5-[4-(1-Methyl-2-oxo-2,3-dihydro-1H-indol-

6-yl)-phenyl]-[1,2,3]triazol-1-yl}-cyclopentyl)-propionamide,

“A78”

N-((1S,3R)-3-{5-[4-(6-Methyl-1H-indazol-5-yl)-phenyl]-

[1,2,3]triazol-1-yl}-cyclopentyl)-propionamide,

“A79”

N-((1S,3R)-3-{5-[4-(2-Oxo-2,3-dihydro-1H-indol-5-yl)-

phenyl]-[1,2,3]triazol-1-yl}-cyclopentyl)-propionamide,

“A80”

N-{(1S,3R)-3-[5-(4′-Cyano-3′-fluoro-biphenyl-4-yl)-

[1,2,3]triazol-1-yl]-cyclopentyl}-propionamide,

“A81”

N-{(1S,3R)-3-[5-(4′-Chloro-2′-fluoro-biphenyl-4-yl)-

[1,2,3]triazol-1-yl]-cyclopentyl}-propionamide,

“A82”

N-{(1S,3R)-3-[5-(4′-Methoxy-2′-methyl-biphenyl-4-yl)-

[1,2,3]triazol-1-yl]-cyclopentyl}-propionamide,

“A83”

N-{(1S,3R)-3-[5-(3′-Fluoro-4′-methyl-biphenyl-4-yl)-

[1,2,3]triazol-1-yl]-cyclopentyl}-propionamide,

“A84”

N-{(1S,3R)-3-[5-(4′-Methyl-biphenyl-4-yl)-[1,2,3]triazol-

1-yl]-cyclopentyl}-propionamide,

“A85”

N-{(1S,3R)-3-[5-(3′-Chloro-4′-fluoro-biphenyl-4-yl)-

[1,2,3]triazol-1-yl]-cyclopentyl}-propionamide,

“A86”

N-{(1S,3R)-3-[5-(2′,4′-Dimethoxy-biphenyl-4-yl)-

[1,2,3]triazol-1-yl]-cyclopentyl}-propionamide,

“A87”

N-((1S,3R)-3-{5-[4-(2-Oxo-2,3-dihydro-1H-benzimidazol-

5-yl)-phenyl]-[1,2,3]triazol-1-yl}-cyclopentyl)-propionamide,

“A88”

N-{(1S,3R)-3-[5-(3′,4′-Dimethoxy-biphenyl-4-yl)-

[1,2,3]triazol-1-yl]-cyclopentyl}-propionamide,

“A89”

N-{(1S,3R)-3-[5-(2′,4′-Dimethyl-biphenyl-4-yl)-

[1,2,3]triazol-1-yl]-cyclopentyl}-propionamide,

“A90”

(S)-2,2-Dimethyl-[1,3]dioxolane-4-carboxylic acid {(1S,3R)-

3-[5-(4-benzoxazol-2-yl-phenyl)-[1,2,3]triazol-1-yl]-

cyclopentyl}-amide,

“A91”

N-((1S,3R)-3-{5-[4-(2-Oxo-2,3-dihydro-1H-indol-6-yl)-phenyl]-

[1,2,3]triazol-1-yl}-cyclopentyl)-propionamide,

“A92”

N-{(1S,3R)-3-[5-(4′-Cyclopropylmethoxy-biphenyl-4-yl)-

[1,2,3]triazol-1-yl]-cyclopentyl}-propionamide,

“A93”

(S)-N-{(1S,3R)-3-[5-(4-Benzoxazol-2-yl-phenyl)-[1,2,3]triazol-

1-yl]-cyclopentyl}-2,3-dihydroxy-propionamide,

“A94”

N-{(1S,3R)-3-[3-(4′-Methoxy-2′-methyl-biphenyl-4-yl)-

[1,2,4]triazol-4-yl]-cyclopentyl}-propionamide,

“A95”

N-{(1S,3R)-3-[3-(4′-Chloro-3′-fluoro-biphenyl-4-yl)-

[1,2,4]triazol-4-yl]-cyclopentyl}-propionamide,

“A96”

N-{(1S,3R)-3-[3-(4′-Pyrazol-1-yl-biphenyl-4-yl)-

[1,2,4]triazol-4-yl]-cyclopentyl}-propionamide,

“A97”

N-((1S,3R)-3-{3-[4-(1-Methyl-1H-indol-5-yl)-phenyl]-

[1,2,4]triazol-4-yl}-cyclopentyl)-propionamide,

“A98”

N-((1S,3R)-3-{3-[4-(6-Methyl-1H-indazol-5-yl)-phenyl]-

[1,2,4]triazol-4-yl}-cyclopentyl)-propionamide,

“A99”

4′-[3-((1R,3S)-3-Ethylcarbamoyl-cyclopentyl)-3H-

[1,2,3]triazol-4-yl]-biphenyl-4-carboxylic acid amide,

“A100”

4′-[3-((1R,3S)-3-Ethylcarbamoyl-cyclopentyl)-3H-

[1,2,3]triazol-4-yl]-biphenyl-4-carboxylic acid,

“A101”

(1S,3R)-3-[5-(4′-Isopropyl-biphenyl-4-yl)-[1,2,3]triazol-

1-yl]-cyclopentanecarboxylic acid ethylamide,

“A102”

(1S,3R)-3-[5-(3′,4′-Dimethoxy-biphenyl-4-yl)-[1,2,3]triazol-

1-yl]-cyclopentanecarboxylic acid ethylamide,

“A103”

(1S,3R)-3-[5-(4′-Cyclopropylmethoxy-biphenyl-4-yl)-

[1,2,3]triazol-1-yl]-cyclopentanecarboxylic acid ethylamide,

“A104”

(1S,3R)-3-[5-(4′-Chloro-3′-fluoro-biphenyl-4-yl)-

[1,2,3]triazol-1-yl]-cyclopentanecarboxylic acid ethylamide,

“A105”

(1S,3R)-3-[5-(4′-Cyano-3′-fluoro-biphenyl-4-yl)-

[1,2,3]triazol-1-yl]-cyclopentanecarboxylic acid ethylamide,

“A106”

(1S,3R)-3-[5-(4′-Cyano-2′-fluoro-biphenyl-4-yl)-

[1,2,3]triazol-1-yl]-cyclopentanecarboxylic acid ethylamide,

“A107”

N-((1S,3R)-3-{5-[6-(1H-Indol-5-yl)-pyridin-3-yl]-

[1,2,3]triazol-1-yl}-cyclopentyl)-propionamide,

“A108”

N-((1S,3R)-3-{5-[6-(4-Fluoro-1H-indol-5-yl)-pyridin-3-yl]-

[1,2,3]triazol-1-yl}-cyclopentyl)-propionamide,

“A109”

N-{(1S,3R)-3-[5-(6-Imidazo[1,2-a]pyridin-6-yl-pyridin-3-yl)-

[1,2,3]triazol-1-yl]-cyclopentyl}-propionamide,

“A110”

N-((1S,3R)-3-{5-[4-(4-Fluoro-1H-indol-5-yl)-phenyl]-

[1,2,3]triazol-1-yl}-cyclopentyl)-propionamide,

“A111”

N-{(1S,3R)-3-[5-(4-Imidazo[1,2-a]pyridin-6-yl-phenyl)-

[1,2,3]triazol-1-yl]-cyclopentyl}-propionamide,

“A112”

N-((1S,3R)-3-{5-[4-(6-Fluoro-1H-indol-5-yl)-phenyl]-

[1,2,3]triazol-1-yl}-cyclopentyl)-propionamide,

“A113”

N-((1S,3R)-3-{5-[4-(1H-Pyrrolo[3,2-b]pyridin-5-yl)-phenyl]-

[1,2,3]triazol-1-yl}-cyclopentyl)-propionamide,

“A114”

N-((1S,3R)-3-{5-[5-(6-Chloro-benzoxazol-2-yl)-pyridin-

2-yl]-[1,2,3]triazol-1-yl}-cyclopentyl)-propionamide,

“A115”

N-{(1S,3R)-3-[5-(5-Benzoxazol-2-yl-pyridin-2-yl)-

[1,2,3]triazol-1-yl]-cyclopentyl}-propionamide,

“A116”

N-((1S,3R)-3-{5-[5-(4-Fluoro-1H-indol-5-yl)-pyridin-2-yl]-

[1,2,3]triazol-1-yl}-cyclopentyl)-propionamide,

“A117”

N-((1S,3R)-3-{5-[5-(1H-Indol-5-yl)-pyridin-2-yl]-

[1,2,3]triazol-1-yl}-cyclopentyl)-propionamide,

“A118”

N-((1S,3R)-3-{5-[5-(1H-Pyrrolo[3,2-b]pyridin-5-yl)-

pyridin-2-yl]-[1,2,3]triazol-1-yl}-cyclopentyl)-propionamide,

“A119”

N-((1S,3R)-3-{5-[3-Fluoro-4-(4-fluoro-1H-indol-5-yl)-phenyl]-

[1,2,3]triazol-1-yl}-cyclopentyl)-propionamide,

“A120”

N-((1S,3R)-3-{5-[3-Fluoro-4-(6-fluoro-1H-indol-5-yl)-phenyl]-

[1,2,3]triazol-1-yl}-cyclopentyl)-propionamide,

“A121”

N-((1S,3R)-3-{5-[6-(1H-Indol-6-yl)-pyridin-3-yl]-

[1,2,3]triazol-1-yl}-cyclopentyl)-propionamide,

“A122”

N-((1S,3R)-3-{5-[6-(1-Methyl-1H-indol-6-yl)-pyridin-3-yl]-

[1,2,3]triazol-1-yl}-cyclopentyl)-propionamide, and

“A123”

N-((1S,3R)-3-{5-[6-(1H-Indazol-4-yl)-pyridin-3-yl]-

[1,2,3]triazol-1-yl}-cyclopentyl)-propionamide

and pharmaceutically acceptable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

10. Process for the preparation of compounds of the formula I according to claim 1 and pharmaceutically acceptable salts, tautomers and stereoisomers thereof, characterised in that

a compound of the

wherein R denotes Br,

Y denotes —CO—W or —N(R 4 )CO—W 1 ,

W denotes NR 2 R 2′ , CH 2 Het 1 , A, Cyc, Ar, CH 2 Ar, —CONR 2 R2′ or Het 1 ,

W 1 denotes NR 2 R 2′ , Het 1 , CH 2 Het 1 , A, Cyc, Ar, CH 2 Ar, CH 2 Cyc or CH(OH)CH 2 OH,

R 1 denotes H, F, Cl, Br, OH, CN, NO 2 , A′, OA′, SA′, SO 2 Me, COA′, CONH 2 , CONHA′ or CONA′ 2 ,

R 2 and R 2′ each, independently of one another, denote H, A or [C(R 3 ) 2 ] n Cyc,

X 1 , X 2 , X 3 each, independently of one another, denote CR 8 or N,

X 4 denotes CR 8 or N,

X 5 denotes CR 8 or N,

R 4 denotes H or A′,

A denotes unbranched or branched alkyl with 1-10 C-atoms, wherein two adjacent carbon atoms may form a double bond and/or one or two non-adjacent CH- and/or CH 2 -groups may be replaced by N-, O- and/or S-atoms and wherein 1-7 H-atoms may be replaced by R 5 ,

Cyc denotes cycloalkyl with 3-7 C-atoms, which is unsubstituted or monosubstituted by OH, Hal or A,

A′ denotes unbranched or branched alkyl with 1-6 C-atoms, wherein 1-5 H-atoms may be replaced by F,

R 5 denotes F, Cl or OH,

Ar denotes phenyl, which is unsubstituted or mono-, di-, tri-, tetra- or pentasubstituted by Hal, A, O[C(R 3 ) 2 ] n Het 1 , Ar 1 , [C(R 3 ) 2 ] n OR 3 , [C(R 3 ) 2 ] p N(R 3 ) 2 , NO 2 , CN, [C(R 3 ) 2 ] p COOR 3 , CON(R 3 ) 2 , Het 1 , OCH 2 Cyc, N(R 3 ) 2 COA, NR 3 SO 2 A, [C(R 3 ) 2 ] p SO 2 N(R 3 ) 2 , S(O) n A, O[C(R 3 )] m N(R 3 ) 2 , NHCOOA, NHCON(R 3 ) 2 and/or COA,

Ar 1 denotes phenyl or naphthyl, which is unsubstituted or mono-, di-, tri-, tetra- or pentasubstituted by Hal, A, [C(R 3 ) 2 ] p OR 3 , [C(R 3 )] 2 ] p N(R 3 ) 2 , NO 2 , CN, [C(R 3 ) 2 ] p COOR 3 , [C(R 3 ) 2 ] p N(R 3 ) 2 , N(R 3 ) 2 COA, NR 3 SO 2 A, [C(R 3 ) 2 ] p SO 2 N(R 3 ) 2 , S(O) n A, O[C(R 3 ) 2 ] m N(R 3 ) 2 , NHCOOA, NHCON(R 3 ) 2 and/or COA,

R 3 denotes H or unbranched or branched alkyl with 1-6 C-atoms,

R 8 denotes H or A′,

Het denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which is unsubstituted or mono-, di-, tri-, tetra- or pentasubstituted by Hal, A, [C(R 3 ) 2 ] n OR′, [C(R 3 ) 2 ] n N(R 3 ) 2 , SR 3 , NO 2 , CN, COOR 3 , CON(R 3 ) 2 , COHet 1 , NR 3 COA, NR 3 SO 2 A, SO 2 N(R 3 ) 2 , S(O) n A, O[C(R 3 ) 2 ] m N(R 3 ) 2 , NHCOOA, NHCON(R 3 ) 2 , CHO, COA, ═S, ═NH, ═NA and/or ═O (carbonyl oxygen),

Het 1 denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which is unsubstituted or mono-, di-, tri-, tetra- or pentasubstituted by Hal, A, [C(R 3 ) 2 ] n OR 3 , [C(R 3 ) 2 ] n N(R 3 ) 2 , SR 3 , NO 2 , CN, COOR 3 , CON(R 3 ) 2 , NR 3 COA, NR 3 SO 2 A, SO 2 N(R 3 ) 2 , S(O) n A, O[C(R 3 ) 2 ] m N(R 3 ) 2 , NHCOOA, NHCON(R 3 ) 2 , CHO, COA, ═S, ═NH, ═NA and/or ═O (carbonyl oxygen),

Hal denotes F, Cl, Br or I,

m denotes 1, 2 or 3,

n denotes 0, 1 or 2,

p denotes 0, 1,2, 3 or 4, q denotes 0, 1, 2 or 3,

is reacted with a compound of the formula II

R—Z  II

in which R denotes Ar or Het,

and Z denotes H,

or Z denotes a boronic acid or a boronic acid ester group, in a Suzuki-type coupling,

and/or

a base or acid of the formula I is converted into one of its salts.

11. Medicaments comprising at least one compound of the formula I of claim 1 and/or pharmaceutically acceptable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, and optionally an pharmaceutically acceptable carrier, excipient or vehicle.

12. A medicament composition comprising at least one compound of the formula I of claim 1 and/or pharmaceutically acceptable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, and at least one further medicament active ingredient.

13. Set (kit) consisting of separate packs of

(a) an effective amount of a compound of the formula I of claim 1 and/or pharmaceutically acceptable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios,

and

(b) an effective amount of a further medicament active ingredient.